A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: Clinical and research implications

Journal of Psychopharmacology

Volumn 26, Issue , 2012, Pages 52-61

  Beary, Michael ^a   Hodgson, Richard ^b   Wildgust, Hiram J ^c  

^a Southgate   (United Kingdom)

^b Lyme Brook Centre   (United Kingdom)

^c Hiram Consulting Ltd   (United Kingdom)

Author keywords

Body mass index; cardiorespiratory fitness; diabetes; first episode; hypertension; modifiable risk factors; mortality; physical activity; prejudice; schizophrenia; smoking

Indexed keywords

HUMAN; HYPERTENSION; MORTALITY; OBESITY; REVIEW; RISK FACTOR; SCHIZOPHRENIA;

HUMANS; HYPERTENSION; OVERWEIGHT; RISK FACTORS; SCHIZOPHRENIA;

EID: 84866253279     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112440512     Document Type: Review

References (131)

1. Allgulander C (1989) Psychoactive drug use in a general population sample, Sweden: correlates with perceived health, psychiatric diagnoses, and mortality in an automated record-linkage study. Am J Public Health 79(8): 1006–1010.
2. Alvarez-Jiménez M Hetrick SE González-Blanch C. (2008) Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 193(2): 101–107.
3. Ascher-Svanum H Zhu B Ernst FR. (2007) The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entry. Prim Care Companion. J Clin Psychiatry 9: 122–128.
4. Aston J Rechsteiner E Bull N. (2010) Hyperprolactinaemia in early psychosis-not only due to antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 34(7): 1342–1344.
5. Baandrup L Gasse C Jensen VD. (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 71(2): 103–108.
6. Banham L Gilbody S (2010) Smoking cessation in severe mental illness: what works? Addiction 105(7): 1176–1189.
7. Barker DJ Hales CN Fall CH. (1993) Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 36(1): 62–67.
8. Barnett JH Werners U Secher SM. (2007) Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 190: 515–520.
9. Barnes TRE Mutsatsa SH Hutton SB. (2006) Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 188: 237–242.
10. Barnoya J Glantz SA (2005) Cardiovascular effects of secondhand smoke nearly as large as smoking. Circulation 111: 2684–2698.
11. Bjerkeset O Romundstad P Evans J. (2008) Association of adult body mass index and height with anxiety, depression, and suicide in the general population. Am J Epidemiol 167(2): 193–202.
12. Blair SN (2009) Physical inactivity: the biggest public health problem of the 21st century. Br J Sports Med 43: 1–2.
13. Bradley AJ Dinan TJ (2010) A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. J Psychopharmacol 24(11)(Suppl 4): 91–118.
14. Brown S Kim M Mitchell C. (2010) Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 196(2): 116–121.
15. Brunette MF Drake RE Xie H. (2006) Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 32(4): 637–643.
16. Bushe CJ Bradley AJ Doshi S. (2009) Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. Int J Clin Pract 63(12): 1743–1761.
17. Bushe CJ Taylor M Haukka J (2010) Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol 24(11)(Suppl 4): 17–25.
18. Byerly M Suppes T Tran QV. (2007) Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 27(6): 639–661.
19. Catts VS Catts SV O'Toole BI. (2008) Cancer incidence in patients with schizophrenia and their first-degree relatives – a meta-analysis. Acta Psychiatr Scand 117(5): 323–336.
20. Church TS Cheng YJ Earnest CP. (2004) Exercise capacity and body composition as predictors of mortality among men with diabetes. Diabetes Care 1: 83–88.
21. Compton MT Kelley ME Ramsay CE. (2009) Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry 166(11): 1251–1257.
22. Cormac I Creasey S McNeill A. (2010) Impact of a total smoking ban in a high secure hospital. Psychiatrist 34: 413–417.
23. De Hert M Schreurs V Sweers K. (2008) Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 101(1-3): 295–303.
24. De Hert M Dekker JM Wood D. (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24(6): 412–424.
25. De Hert M Cohen D Bobes J (2011a) Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 10(2): 138–151.
26. De Hert M Correll CU Bobes J. (2011b) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10(1): 52–77.
27. Deimel H Lohmann S (1983) Physical capacity of schizophrenic patients. Rehabilitation (Stuttg) 22(2): 81–85.
28. De Meyer T Rietzschel ER De Buyzere ML. (2008) Studying telomeres in a longitudinal population based study. Front Biosci 13: 2960–2970.
29. Dixon L Postrado L Delahanty J. (1999) The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Mental Dis 187(8): 496–502.
30. Dixon LB Kreyenbuhl JA Dickerson FB. (2004) A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses. Psychiatr Serv 55(8): 892–900.
31. Doll R Peto R Boreham J. (2004) Mortality in relation to smoking: 50 years' observations on male British doctors. Br Med J 328: 1519.
32. Drake RE Xie H McHugo GJ. (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26(2): 441–449.
33. Epel ES Blackburn EH Lin J.(2004) Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A 101(49): 17312-17315.
34. Fatemi SH (2001) Reelin mutations in mouse and man: from reeler mouse to schizophrenia, mood disorders, autism and lissencephaly. Mol Psychiatry 6: 129–133.
35. Faulkner G Cohn T Remington G (2007) Interventions to reduce weight gain in schizophrenia. Schizophr Bull 33(3): 654–656.
36. Fernandez-Egea E Bernardo M Heaphy CM. (2009) Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr Bull 35(2): 437–442.
37. Flegal KM Graubard BI Williamson DF. (2007) Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 298(17): 2028–2037.
38. Fogelholm M (2010) Physical activity, fitness and fatness: relations to mortality, morbidity and disease risk factors. A systematic review. Obes Rev 11(3): 202–221.
39. Forsén T Eriksson J Tuomilehto J. (2000) The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med 133: 176–182.
40. Frederic M (2010) Physical therapy at OPUS. Early Interv Psychiatry 4(Supp1): 135.
41. Fu Q Yu X Callaway CW. (2009) Epigenetics: intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene. FASEB J 23(8): 2438–2449.
42. Gorczynski P Faulkner G (2010) Exercise therapy for schizophrenia. Cochrane Database Syst Rev 5: CD004412.
43. Hakko H Wahlberg KE Tienari P. (2011) Genetic vulnerability and premature death in schizophrenia spectrum disorders: A 28-year follow-up of adoptees in the Finnish Adoptive Family Study of Schizophrenia. Nord J Psychiatry 65: 259–265.
44. Hankinson SE Willett WC Michaud DS. (1999) Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91(7): 629–634.
45. Hamer M Stamatakis E Steptoe A (2008) Psychiatric hospital admissions, behavioral risk factors, and all-cause mortality: the Scottish health survey. Arch Intern Med 168(22): 2474–2479.
46. Hawton K Sutton L Haw C. (2005) Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 187: 9–20.
47. Hemmingsson T Kriebel D (2003) Smoking at age 18–20 and suicide during 26 years of follow-up – how can the association be explained? Int J Epidemiol 32(6): 1000–1004.
48. Hodgson R Wildgust HJ Bushe CJ (2010) Review: Cancer and schizophrenia: is there a paradox? J Psychopharmacology 24(11)(Suppl 4): 51–60.
49. Hor K Taylor M (2010) Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 24(11)(Suppl 4): 81–90.
50. Joukamaa M Heliovaara M Knekt P. (2006) Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188: 122–127.
51. Kahn RS Fleischhacker WW Boter H. (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371(9618): 1085–1097.
52. Kang JH Xirisagar S Lin HC (2011) Lower mortality among stroke patients with schizophrenia: a nationwide population-based study. Psychosom Med 73:106–111.
53. Kaplan MS McFarland BH Huguet N (2007a) The relationship of body weight to suicide risk among men and women: results from the US National Health Interview Survey Linked Mortality File. J Nerv Ment Dis 195(11): 948–951.
54. Kaplan MS Huguet N McFarland BH. (2007b) Suicide among male veterans: a prospective population based study. J Epidemiol Community Health 61: 619–624.
55. Katz J Kunofskyr S Patton RE. (1967) Cancer mortality among patients in New York mental hospitals. Cancer 20(12): 2194–2199.
56. Kelly C McCreadie RG (1999) Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 156: 1751–1757.
57. Kelly DL McMahon RP Wehring HJ. (2009) Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull (Advance Access) published doi:10.1093/schbul/sbp15210.1093/schbul/sbp152.
58. Khaw K Wareham N Bingham S. (2008) Combined impact of health behaviours and mortality in men and women: The EPIC-Norfolk Prospective Population Study. PLoS Med 5(1): e12.
59. Khuder SA Milz S Jordan T. (2007) The impact of a smoking ban on hospital admissions for coronary heart disease. Prev Med 45(1): 3-8.
60. Kilbourne AM Morden NE Austin K. (2009) Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry 31: 555–563.
61. Kirkpatrick B Messias E Harvey PD. (2008) Is schizophrenia a syndrome of accelerated aging? Schizophr Bull 34(6):1024–1032.
62. Kisely S Campbell LA Wang Y (2009) Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare. Br J Psychiatry 195: 545–550.
63. Kisely S Sadek J MacKenzie A. (2008) Excess cancer mortality in psychiatric patients. Can J Psychiatry 53(11): 753–761.
64. Kodama S Saito K Tanaka S. (2009) Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 301(19): 2024–2035.
65. Kohen D (2004) Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl 47: S64–S66.
66. Kohen D Wildgust HJ (2008) The evolution of hyperprolactinaemia as an entity in psychiatric patients. J Psychopharmacol 22(Suppl 2): 6–11.
67. Koivukangas J Tammelin T Kaakinen M. (2010) Physical activity and fitness in adolescents at risk for psychosis within the Northern Finland 1986 Birth Cohort. Schizophr Res 116(2): 152–158.
68. Kuh D Hardy R Chaturvedi N Wadsworth ME (2002) Birth weight, childhood growth and abdominal obesity in adult life. Int J Obes Relat Metab Disord 26: 40–47.
69. Kuk JL Katzmarzyk PT Nichaman MZ. (2006) Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) 14(2): 336–341.
70. Kunugi H Nanko S Murray RM (2001) Obstetric complications and schizophrenia: prenatal underdevelopment and subsequent neurodevelopmental impairment. Br J Psychiatry 178: S25–S29.
71. Kuruvilla A Peedicayil J Srikrishna G. (1992) A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 19: 603–606.
72. Lambert TJ Velakoulis D Pantelis C (2003) Medical comorbidity in schizophrenia. Med J Aust 178(Suppl): S67–S70.
73. Laursen TM Munk-Olsen T Agerbo E. (2009) Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry 66(7): 713–720.
74. Lawrence D Holman CD Jablensky AV. (2000) Excess cancer mortality in western Australian psychiatric patients due to higher case fatality rates. Acta Psychiatr Scand 101(5): 382–388.
75. Lawrence D Kisely S (2010) Inequalities in healthcare provision for people with severe mental illness. J Psychopharmacology (4 Suppl): 61–68.
76. Lee DC Artero EG Sui X. (2010) Mortality trends in the general population: the importance of cardiorespiratory fitness. J Psychopharmacol 24(11)(Suppl 4): 27–35.
77. Leucht S Burkard T Henderson J. (2007) Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 116: 317–333.
78. Limosin F Loze JY Philippe A. (2007) Ten-year prospective follow-up study of the mortality by suicide in schizophrenic patients. Schizophr Res 94(1–3): 23–28.
79. Lindamer LA McKibbin C Norman GJ. (2008) Assessment of physical activity in middle-aged and older adults with schizophrenia. Schizophr Res 104(1-3): 294–301.
80. McEvoy JP Lieberman JA Perkins DO. (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164(7): 1050–1060.
81. Magnusson PK Rasmussen F Lawlor DA. (2006) Association of body mass index with suicide mortality: a prospective cohort study of more than one million men. Am J Epidemiol 163(1): 1–8.
82. Malik VS Popkin BM Bray GA. (2010) Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation 121(11): 1356–1364.
83. Menza M Vreeland B Minsky S. (2004) Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 65(4): 471–477.
84. Miller M Hemenway D Rimm E (2000) Cigarettes and suicide: a prospective study of 50,000 men. Am J Public Health 90(5): 768–773.
85. Minami J Ishimitsu T Matsuoka H (1999) Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. Hypertension 33: 586–590.
86. Mitchell AJ Dinan TJ (2010) Schizophrenia: A multisystem disease. J Psychopharmacol 24(11)(Suppl 4): 5–7.
87. Mitchell AJ Lord O (2010) Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis. J Psychopharmacol 24(11)(Suppl 4): 69–91.
88. Mokdad AH Marks JS Stroup DF. (2004) Actual causes of death in the United States, 2000. JAMA 291: 1238–1245.
89. Mozaffarian D Kamineni A Carnethon M. (2009) Lifestyle risk factors and new-onset diabetes mellitus in older adults: the cardiovascular health study. Arch Intern Med 169(8): 798–807.
90. Mukamal KJ Kawachi I Miller M. (2007) Body mass index and risk of suicide among men. Arch Intern Med 167(5): 468–475.
91. Mukamal KJ Rimm EB Kawachi I. (2010) Body mass index and risk of suicide among one million US adults. Epidemiology 21(1): 82–86.
92. Mukamal JK Wee CC Miller M (2009) BMI and rates of suicide in the United States: An ecological analysis. Obesity 17: 1946–1950.
93. Myers J Prakash M Froelicher V. (2002) Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 346: 793–801.
94. Nasrallah HA Meyer JM Goff DC. (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86(1-3): 15–22.
95. NICE (National Institute for Clinical Excellence) (2002a) Schizophrenia core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical Guideline 1. London: NICE.
96. NICE (National Institute for Clinical Excellence) (2002b) Guidance in the use of newer atypical antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance No 43. London: NICE.
97. Nielsen J Skadhede S Correll CU (2010) Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 35: 1997–2004
98. Ong KK (2006) Size at birth, postnatal growth and risk of obesity. Horm Res 65(Suppl. 3): 65–69.
99. Osborn DPJ Wright CA Levy G. (2008) Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: Systematic review and metaanalysis. BMC Psychiatry 8: 84.
100. Puterman E Lin J Blackburn E. (2010) The power of exercise: buffering the effect of chronic stress on telomere length. PLoS One 5(5): e10837.
101. Rader DJ Cohen J Hobbs HH (2003) Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 111(12): 1795–1803.
102. Ray KK Seshasai SRK Erqou S. (2010) Statins and all-cause mortality in high-risk primary prevention. Arch Intern Med 17(12): 1024–1031.
103. Saha S Chant D McGrath J (2007) A systematic review of mortality in schizophrenia. Arch Gen Psychiatry 64(10):1123–1131.
104. Sattar N Preiss D Murray HM. (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716): 735–742.
105. Segal M Avital A Rojas M. (2004) Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes. Psychiatry Res 127(3): 227–235.
106. Sengupta S Parrilla-Escobar MA Klink RA. (2008) Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls? Schizophr Res 102: 329–336.
107. Sørensen TI Rissanen A Korkeila M. (2005) Intention to lose weight, weight changes, and 18-y mortality in overweight individuals without co-morbidities. PLoS Med 2(6): e171.
108. Spelman LM Walsh PI Sharifi N Collins P Thakore JH (2007) Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 24: 481–485.
109. Stamler J Daviglus ML Garside DB. (2000) Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 284(3): 365–367.
110. Strassnig M Miewald J Keshavan M. (2007) Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res 93(1–3): 90–98.
111. Taylor D Paton C Kapur S (2009) Prescribing Guidelines. Informa Health Care.
112. Taylor F Ward K Moore THM. (2011) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1: CD004816.
113. Thakore JH Mann JN Vlahos I. (2002) Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 26(1): 137–141.
114. Tiihonen J Haukka J Taylor M. (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168: 603–609.
115. Tiihonen J Lönnqvist J Wahlbeck K. (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690): 620–627.
116. Tiihonen J Walhbeck K Lönnqvist J. (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Br Med J 333(7561): 224–227.
117. Tosh G Clifton A Mala S Bachner M (2010) Physical health care monitoring for people with serious mental illness. Cochrane Database Syst Rev 3: CD008298.
118. Tran E Rouillon F Loze JY. (2009). Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer 115(15): 3555–3562.
119. Tsoi DT Porwal M Webster AC (2010) Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 6: CD007253.
120. Tworoger SS Eliassen AH Rosner B. (2004) Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64: 6814–6819.
121. Tworoger S Eliassen H Sluss P. (2007) A prospective study of plasma prolactin concentrations and the risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 25(12): 1–7.
122. Vancampfort D Knapen J De Hert M. (2009) Cardiometabolic effects of physical activity interventions for people with schizophrenia. Phys. Ther. Rev. 14(6): 388–398.
123. Vinogradova Y Coupland C Hippisley-Cox J (2010) Effects of severe mental illness on survival of people with diabetes. Br J Psychiatry 197: 272–277.
124. Waddington JL Youssef HA Kinsella A (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173: 325–329.
125. Weinmann S Read J Aderhold V (2009) Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 113(1): 1–11.
126. Werneke U Horn O Maryon-Davis A. (2006) Uptake of screening for breast cancer in patients with mental health problems. J Epidemiol Community Health 60(7): 600–605.
127. WHO (2009) Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization.
128. Wildgust HJ Beary M (2010) Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? J Psychopharmacol 24(11)(Suppl 4): 37–50.
129. Willi C Bodenmann P Ghali WA. (2007). Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 298(22): 2654–2664.
130. Zhang ZJ Yao ZJ Liu W. (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184: 58–62.
131. Zipursky RB Gu H Green AI. (2005) Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 187: 537–543.